Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: * Advanced Non-Small Cell Lung Cancer * Measurable Target Lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Failed all standard of care including chemotherapy, targeted therapy, and immunotherapy * Adults over 18 years * Performance status (Eastern Cooperative Oncology Group) less than or equal to 2 * Life expectancy greater than 2 months * Laboratory Values: Hemoglobin greater than or equal to 9; neutrophils greater than 1,000; platelets greater than 50,000 Liver function tests less than or equal to twice upper limit of normal Serum Creatinine less than or equal to 2 Creatinine clearance greater than or equal to 30 mL per minute Hemoglobin A1C less than 7 Normal Thyroid function * No history of hyperthyroidism * Abstinence from alcohol and supplements * Not pregnant, lactating and willing to use birth control throughout study * Able to provide consent * Positive Emission Tomography/Computer Tomography part of subjects care plan at baseline Exclusion Criteria: * Prior use of Withania somnifera * Phenylketonuria * Inability to swallow capsules * Hypersensitivity to study drug ingredients * Unstable medical or surgical condition * History of additional cardiac risk factors * Requiring drugs that are "strong" inhibitors of cytochrome P450 * Requiring irradiation * Requiring intravenous fluids or hyperalimentation * Requiring transfusions, dialysis, or other procedures * Active infection * Human Immunodeficiency Virus * Must exceed washout period of prior treatments * Psychiatric, neurological or other reason that precludes subjects ability to participate